The researchers concluded that Oxyjun “could improve cardiac pumping capacity by significantly increasing LVEF and reducing fatigue in a diverse, healthy population.”
A recent study1 published in the Journal of Multidisciplinary Healthcare found that a proprietary, standardized aqueous extract of Terminalia arjuna bark, called Oxyjun, from Enovate Biolife (Wilmington, DE), may support cardiovascular health in healthy adults. In the study, 72 healthy adults between the ages of 30 and 70 years were given either 400 mg per day of Oxyjun or a matching placebo for eight weeks. Researchers investigated the effects of the invention on myocardial pumping capacity, primarily left ventricular ejection fraction (LVEF). Secondary endpoints included improvement in diastolic filling (E/A) ratio, rate pressure product (RPP), and fatigue severity scale (FSS) score, as well as the effects on blood lipids and gamma-glutamyltransferase (GGT) levels.
Results showed that subjects taking Oxyjun saw a 6.28% increase in LVEF from baseline compared to a 0.24% increase in the placebo group. The extact also reduced fatigue by 22.52%, RPP by 1.54% and GGT levels by 5.9%. The researchers concluded that Oxyjun “could improve cardiac pumping capacity by significantly increasing LVEF and reducing fatigue in a diverse, healthy population.”
This is significant because reductions in LVEF may have a detrimental effect on heart health, as well as increase fatigue and feelings of exertion during physical activity. Some research suggests that every decade we age LVEF decreases by 1%, therefore managing LVEF as we age can be crucial for reducing the risk of heart disease.